TD Cowen Downgrades CRISPR Therapeutics to Underperform, Announces $30 Price Target
Portfolio Pulse from Benzinga Newsdesk
TD Cowen analyst Tyler Van Buren has downgraded CRISPR Therapeutics (CRSP) from Market Perform to Underperform and set a price target of $30.
December 11, 2023 | 12:24 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
CRISPR Therapeutics downgraded by TD Cowen to Underperform with a $30 price target, indicating a bearish outlook.
Downgrades by analysts can lead to a negative perception among investors and potential sell-off. The new price target of $30 suggests a bearish view on the stock's future performance, which could result in downward pressure on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100